News
Article
Author(s):
FDA mandates new opioid labeling to highlight long-term risks, aiming to combat addiction and improve patient safety in pain management.
The required rework to opioid medication labels will see an increased emphasis and explanation of the associated risks of long-term usage.
Stock.adobe.com
FDA announced a change in its policy, now requiring all opioid pain medications to place a greater emphasis on, as well as provide an explanation of, the risks accompanied by long-term usage. These changes followed a public advisory committee meeting back in May of this year examining data that displayed severe risks of misuse, addiction and fatal & non-fatal overdoses amongst long-term users, igniting FDA’s decision to make a change.
FDA Commissioner Marty Makary, M.D., M.P.H., touched on the decision, saying, “The death of almost one million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment. This long-overdue labeling change is only part of what needs to be done we also need to modernize our approval processes and post-market monitoring so that nothing like this ever happens again.”1
The rework to opioid medication labels is supported with an expansive data set provided by FDA’s own required observational studies titled postmarketing requirements (PMR). FDA employed two of its PMRs (3033-1 & 3033-2) to provide supporting data on the side effects of long-term opioid usage alongside researching through public comments and medical studies and concluded that medical history records are devoid of adequate studies of long-term opioid use. This directed the FDA to request the safety changes to opioid labels to better inform patients and healthcare professionals allowing them to make the safest and research supported decisions.
Following FDA’s decision to update opioid medication labels, letters were sent to relevant recipients across the opioid medication industry outlining the requested alterations to medication labels. Recipients will be granted with a 30-day window to submit label updates for review.
Accompanying the safety label change, the FDA will also be mandating randomized and controlled clinical trials examining the benefits and risks associated with long-term opioid usage. FDA reports it will be closely monitoring these trials to ensure completion in a timely and efficient manner.
Opioid medication labels will also see the following changes according to the new requirements:
HHS Secretary Robert F. Kennedy, Jr. talked about the impact of opioid addiction and the benefits these label changes will bring, saying, “I know firsthand how devastating addiction is not just for individuals, but for entire families and communities. Today’s FDA action is a long-overdue step toward restoring honesty, accountability, and transparency to a system that betrayed the American people.”1
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
